MedPacto Company Description

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea.

The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors.

MedPacto, Inc. is based in Seoul, South Korea.

MedPacto, Inc.

Country	South Korea
Industry	Biotechnology
Sector	Healthcare
CEO	Seong-Jin Kim

Contact Details

Address: Borim Building Seoul, 06668 South Korea
Phone	82 2 6938 0200
Website	medpacto.com

Stock Details

Ticker Symbol	235980
Exchange	KOSDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	KRW
ISIN Number	KR7235980000
SIC Code	2836

Key Executives

Name	Position
Seong-Jin Kim	Chief Executive Officer